Historical correlations indicate akba stock price forecast often mirrors sentiment in the Nasdaq Biotech Index, particularly during earnings seasons. Over half a decade Akebia Therapeutics reduced its trailing twelve month revenue by 12% for each year. That puts it in an unattractive cohort, to put it mildly. So it's not altogether surprising to see the share price down 12% per year in the same time period. We don't think this is a particularly promising picture. Of course, the poor performance could mean the market has been too severe selling down. That can happen. Some other drug/biotech companies worth considering are Roche RHHBY, Arcturus Therapeutics Holdings ARCT and Eli Lilly LLY. While Roche and Arcturus Therapeutics Holdings sport a Zacks Rank #1 (Strong Buy) each, Lilly has a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Some analysts tie akba stock price forecast strength to possible expansion of its therapeutic portfolio, which could re-rate the stock.